How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Education and Training · Forecast 2027–2033
AAT Test Market
- By Test Methodology: Serum Protein Electrophoresis (SPE), Immunonephelometry, Immunoturbidimetry, Radial Immunodiffusion (RID), Enzyme-Linked Immunosorbent Assay (ELISA)
- By Sample Type: Serum, Plasma, Whole Blood, Dried Blood Spot (DBS)
- By End-User: Clinical Laboratories, Hospital Laboratories, Reference Laboratories, Point-of-Care Testing Facilities
- By Application: Alpha-1 Antitrypsin Deficiency Diagnosis, Chronic Obstructive Pulmonary Disease (COPD) Management, Liver Disease Assessment, Genetic Screening
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Serum Protein Electrophoresis (SPE) leads By Test Methodology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 9 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 260 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 9 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the AAT Test Market report
A complete, evidence-based study - 11 chapters and 109 sections covering market size, segmentation across 4 axes, regional analysis and 9 company profiles, forecast to 2033.
Segmentation covered
Test Methodology 5
Sample Type 4
End-User 4
Application 4
Companies profiled
Alpha Laboratories
Biobase Group
ELITechGroup
Horiba Medical.
Laboratory Corporation of America Holdings
Randox Laboratories Ltd
Thermo Fisher Scientific Inc.
Abbott Laboratories
Roche Diagnostics
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
9 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Alpha Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Biobase Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →ELITechGroup
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Horiba Medical.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Laboratory Corporation of America Holdings
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Randox Laboratories Ltd
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Thermo Fisher Scientific Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Abbott Laboratories
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.196 →Roche Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,819M by 2033 · 6.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Serum Protein Electrophoresis (SPE)54.7
- Immunonephelometry14.6
- Immunoturbidimetry13.9
- Radial Immunodiffusion (RID)8.7
- Enzyme-Linked Immunosorbent Assay (ELISA)8.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$789.4M → $1,367M · 7.1%
Europe$550.2M → $890.2M · 6.2%
Asia Pacific$502.4M → $744.4M · 5.0%
Latin America$311.0M → $454.3M · 4.9%
Middle East and Africa$239.2M → $401.1M · 6.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.982026
5.992027
6.002028
6.012029
6.022030
6.042031
6.052032
6.062033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Alpha Laboratories14.8
- Biobase Group17.0
- ELITechGroup11.9
- Horiba Medical.11.4
- Laboratory Corporation of America Holdings9.2
- Randox Laboratories Ltd7.9
- Others27.8
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Methodology26.5%
Sample Type38.3%
End-User12.7%
Application22.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.4
- Europe23.1
- Asia Pacific19.3
- Latin America11.8
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Alpha Laboratories | 87 | 87 | 94 | 94 | 90 | 91 | 91 |
| Biobase Group | 77 | 79 | 88 | 76 | 82 | 72 | 79 |
| ELITechGroup | 72 | 81 | 79 | 66 | 76 | 88 | 77 |
| Horiba Medical. | 67 | 74 | 80 | 61 | 64 | 77 | 71 |
| Laboratory Corporation of America Holdings | 52 | 70 | 52 | 61 | 69 | 70 | 62 |
| Randox Laboratories Ltd | 52 | 56 | 48 | 52 | 60 | 59 | 55 |
| Thermo Fisher Scientific Inc. | 48 | 55 | 43 | 44 | 49 | 61 | 50 |
| Abbott Laboratories | 41 | 57 | 55 | 51 | 46 | 36 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Alpha Laboratories
- Biobase Group
- ELITechGroup
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Alpha Laboratories | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Biobase Group | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| ELITechGroup | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Horiba Medical. | ✓ | ✓ | ◐ | ◐ | − | ◐ |
| Laboratory Corporation of America Holdings | − | ◐ | − | ◐ | ◐ | ◐ |
| Randox Laboratories Ltd | − | ◐ | ◐ | − | − | ◐ |
| Thermo Fisher Scientific Inc. | − | ◐ | − | − | − | ✓ |
| Abbott Laboratories | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Alpha Laboratories91
2Biobase Group79
3ELITechGroup77
4Horiba Medical.71
5Laboratory Corporation of America Holdings62
6Randox Laboratories Ltd55
7Thermo Fisher Scientific Inc.50
8Abbott Laboratories48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Alpha LaboratoriesBiobase Group
Challenger2
Strong scale, closing on the leaders.
ELITechGroupHoriba Medical.
Contender1
Focused players with pockets of strength.
Laboratory Corporation of America Holdings
Niche3
Specialists in a single segment or region.
Randox Laboratories LtdThermo Fisher Scientific Inc.Abbott Laboratories
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Methodology in North America, then scale across AAT Test Market — a $521M beachhead inside a $8.75B market.
Beachhead (SOM)$521Mobtainable near-term
Serviceable (SAM)$3.08Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Serum Protein Electrophoresis (SPE)
Best fit — highest urgency & budget in Test Methodology.
Economic buyer77 fit
Immunonephelometry
Strong fit — clear ROI and a fast path to value.
End user69 fit
Immunoturbidimetry
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Methodology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Sample Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Test Methodology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win AAT Test Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified25%
Evaluation14%
Closed-won6%
$13.5KCAC
$49KLTV
3.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
AAT Test Market is a durable-growth opportunity — $3.08B by 2033, compounding at 7.0%.
TAM · 2025$1.79Btoday
TAM · 2033$3.08Bforecast
CAGR7.0%2027–2033
Cumulative$21.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.08BTotal addressable market
SAM$1.15BServiceable available market
SOM$226MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.0% CAGR
Demand compounds through 2033, outpacing GDP across Test Methodology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Methodology moving from early to mainstream — durable secular demand.
Consolidation upside
9+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.08BLarge & growingTAM by 2033 at 7.0% CAGR
$1.15BServiceable nowreachable with today’s model
$226MBeachhead winobtainable near-term share
9+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.40BBear4.6% CAGR
$3.08BBase7.0% CAGR
$3.94BBull9.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Sample Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
AAT Test Market — a $6.00B market by 2033. Plan: grow share from 11.1% to 18.7%.
Market size · 2033$6.00Btotal addressable
Market CAGR6.9%2027–2033
Target share18.7%from 11.1% today
Revenue ambition$1.12Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.1% | 18.7% | On track |
| Revenue | $683M | $1.12B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.4% | 42.4% | On track |
| Customer retention | 89.8% | 94.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Methodology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Sample Type capability
A defensible second engine — invest in Sample Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Methodology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Sample Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $149M capacity & capability investment
- Greenlight bolt-on M&A in Sample Type
- Authorise North America expansion plan
- Fund R&D program for Test Methodology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAhead
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the AAT Test Market conversation — a $1.59B market you can size, segment and defend in minutes.
Market size · 2033$1.59Btotal opportunity
Growth3.9%CAGR to 2033
Addressable buyers923+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Methodology
Goal Grow share in Test Methodology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 3 mopayback period
$43K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
9+players profiled in this market
Coverage includes
Alpha LaboratoriesBiobase GroupELITechGroupHoriba Medical.Laboratory Corporation of America HoldingsRandox Laboratories LtdThermo Fisher Scientific Inc.Abbott Laboratories+1 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your AAT Test Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
AAT Test Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Education and Training · scroll →Child Care Administrative Software Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportArtificial Intelligence (AI) in Education Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportSchool Administration Software Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportSimulation Learning in Higher Education Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportClassroom Scheduling Software Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportStudent Management Systems Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportOnline Legal Education Tools Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportOnline Music Education Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportHigher Ed CRM Software Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportK-12 Technology Spending Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportK-12 Technology Training for Teachers Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportK-12 Testing and Assessment Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.